Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

_www_larval_com_ Nov. 14 at 6:22 PM

$RLMD just reversed -3% lower to 0% (~2Mv) moments ago, 11/21 options, follow for more volatility.

0 · Reply

misterbond007 Nov. 14 at 4:23 PM

$RLMD take profit now correction coming! 1.50 - 2$

0 · Reply

crett Nov. 14 at 2:43 PM

$RLMD

0 · Reply

TheInside2028 Nov. 14 at 10:28 AM

$RLMD nice read

0 · Reply

TheInside2028 Nov. 14 at 10:23 AM

$RLMD

0 · Reply

TheInside2028 Nov. 14 at 10:22 AM

$RLMD I’ll wait for pullback. We sold close to our 4.37 target. Made bank. Financial were ok

0 · Reply

misterbond007 Nov. 14 at 3:26 AM

$RLMD You have no idea how this stock is going to explode. Yes, we’ll see some corrections, but within 1 to 2 months this stock will be worth more than $50.

1 · Reply

crett Nov. 13 at 10:13 PM

$RLMD Mathematically a beat by $.12 positive than expected.

0 · Reply

misterbond007 Nov. 13 at 9:44 PM

$RLMD correction coming and big bump after

1 · Reply

SadyK189 Nov. 13 at 9:11 PM

Here is my Amazing daily Stocktwits report: $NVVE $SGBX $SPRU $IRWD $RLMD NVVE Price 0.36: My post last night "Getting up on 4hours chart. Key support at 0.25 - 0.28. Next key level to test is 0.45 - 0.48. Currently at 0.36" Again posted today "Next key level to test is 0.64 - 0.68" It went till 0.6450 SGBX My post last night "Getting up on 4hours chart. Key support at 2.15 - 2.35. Next key level to test is 3.65 - 3.85. Currently at 3.07" It hit our desired zone and went till 3.97 SPRU My post last night "Good close of daily candle. Key support at 3.85 - 4.10. Next key level to test is 5.35 - 5.60. Currently at 4.82" It hit our desired zone and went till 5.76 today RLMD: Initially alerted at 2.60. Then posted last night "Next key level to test is 3.85 - 4.20" It hit our desired zone. It went till 4.26 today IRWD: My post was "IRWD is trending nicely on daily chart. 2.15 - 2.35 is acting as key support zone. Next key level to test is 3.35 - 3.55. Currently at 2.95" It went till 3.52 today

0 · Reply

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:01 PM EST - 1 day ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 7 days ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 4, 2025, 7:09 AM EST - 10 days ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:01 AM EST - 10 days ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Oct 7, 2025, 7:30 AM EDT - 5 weeks ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Sep 16, 2025, 9:00 AM EDT - 2 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 2 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 8, 2025, 1:55 PM EDT - 3 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 3 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 4 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 4 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 5 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 10:02 PM EDT - 6 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 6 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 6 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 1:38 PM EDT - 7 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 7 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 7 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 7 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 8:07 PM EDT - 8 months ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 8 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 8 months ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 8 months ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 10 months ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 2:02 PM EST - 1 year ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 10, 2024, 9:39 AM EST - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 19, 2024, 5:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Jul 18, 2024, 5:15 PM EDT - 1 year ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Jul 17, 2024, 3:30 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

Jul 16, 2024, 3:45 PM EDT - 1 year ago

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Jul 15, 2024, 3:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Jul 13, 2024, 7:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

Jul 12, 2024, 6:45 PM EDT - 1 year ago

Potential Securities Violations By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate Dialogue

Jul 11, 2024, 2:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Scrutiny By The Schall Law Firm For Potential Securities Breaches Urging Affected Investors To Initiate Conversation

_www_larval_com_ Nov. 14 at 6:22 PM

$RLMD just reversed -3% lower to 0% (~2Mv) moments ago, 11/21 options, follow for more volatility.

0 · Reply

misterbond007 Nov. 14 at 4:23 PM

$RLMD take profit now correction coming! 1.50 - 2$

0 · Reply

crett Nov. 14 at 2:43 PM

$RLMD

0 · Reply

TheInside2028 Nov. 14 at 10:28 AM

$RLMD nice read

0 · Reply

TheInside2028 Nov. 14 at 10:23 AM

$RLMD

0 · Reply

TheInside2028 Nov. 14 at 10:22 AM

$RLMD I’ll wait for pullback. We sold close to our 4.37 target. Made bank. Financial were ok

0 · Reply

misterbond007 Nov. 14 at 3:26 AM

$RLMD You have no idea how this stock is going to explode. Yes, we’ll see some corrections, but within 1 to 2 months this stock will be worth more than $50.

1 · Reply

crett Nov. 13 at 10:13 PM

$RLMD Mathematically a beat by $.12 positive than expected.

0 · Reply

misterbond007 Nov. 13 at 9:44 PM

$RLMD correction coming and big bump after

1 · Reply

SadyK189 Nov. 13 at 9:11 PM

0 · Reply

crett Nov. 13 at 8:45 PM

$RLMD $100M equity raise bolsters cash & positive FDA feedback on NDV-01. Good chance to be Positive

1 · Reply

_www_larval_com_ Nov. 13 at 8:17 PM

$RLMD has turned -4% lower to 3% (~794Kv) in the last few minutes, 11/21 options, follow for more volatility.

0 · Reply

CrestFresh Nov. 13 at 8:11 PM

$RLMD hmmm looking good for earnings

1 · Reply

crett Nov. 13 at 7:58 PM

$RLMD Buyers coming in

0 · Reply

boomshiva Nov. 13 at 7:50 PM

$RLMD It's the little engine that could.

0 · Reply

misterbond007 Nov. 13 at 6:53 PM

$RLMD It's incredible that no retail traders are interested in these kinds of stocks. A $100M offering of high quality, with over $2M in insider buying from the CEO and CFO. I understand why retail traders never win they only trade based on charts and shitty stocks, and they don't follow the smart money

1 · Reply

BullJack Nov. 13 at 5:40 AM

$RLMD sheesh scrolling through CEO buys and just saw this. this thing is up almost 700% YTD.

0 · Reply

CrestFresh Nov. 13 at 1:42 AM

$RLMD over 4 in overnight

0 · Reply

RunnerSignals Nov. 12 at 9:22 PM

Movers & Shakers! $FTCI $SI $RLMD $ABEO are stealing the spotlight with big moves today https://stocksrunner.com/news/2025-11-12-top-movers-and-shakers-today

0 · Reply

SadyK189 Nov. 12 at 9:03 PM

Here is my Amazing daily Stocktwits report : $CYPH $OPEN $RLMD $RDGT $BW LPTX: Posted at 1.06 that "updated support at 0.89 - 0.93. Next key level to test is 1.22 - 1.35". It ran massively to 2.53 afterwards. OPEN: My post was "Getting up on 4hours chart. Key support at 6.65 - 7.05. Next key level to test is 8.90 - 9.15. Currently at 8.33" It went till 9.15 today RDGT: My post last night "Looking good on daily chart. 2.8 - 3.1 is acting as key support zone. Next key level to test is 4.4 - 4.75. Currently at 3.82" It hit our desired zone and went till 4.55 today RLMD: Initially alerted at 2.60. Then posted last night "Next key level to test is 3.85 - 4.20" It hit our desired zone. It went till 3.95 today BW: Initially alerted at 2.47. Kept posting about it regularly. Then posted "Still looking good on daily chart. Key support at 5.30 - 5.70 now. Next key level to test lies at 7.80 - 8.20" It went till 7.77 today

1 · Reply

_ReddBullyz Nov. 12 at 3:52 PM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $AIFF $INDO $BBBY $RLMD Track'

1 · Reply

Ammikan Nov. 12 at 3:23 PM

$RLMD 6.30 incomming!

0 · Reply

Market Cap	128.79M
Revenue (ttm)	0.00
Net Income (ttm)	-79.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,301,200
Avg Vol	983,086
Day's Range	N/A - N/A
Shares Out	33.19M
Stochastic %K	82%
Beta	0.87
Analysts	Hold
Price Target	$1.00